The U.S. Department of Justice recently released a directive addressing efforts to combat white-collar fraud and explicitly called out enforcement under the Federal Food, Drug, and Cosmetic Act. The directive was published by the DOJ’s National Fraud Enforcement Division and was reported by STAT News Pharmalot. According to the article, the move signals a broadened emphasis on potential violations tied to life sciences companies.
The published story notes that the DOJ has historically focused health-fraud enforcement on providers, clinics, home health agencies, and hospices. The new directive’s language, by expressly including the Federal Food, Drug, and Cosmetic Act, appears to place drug and device manufacturers more visibly within the division’s enforcement priorities.
A central factual point in the report is that the DOJ directive specifically references the Federal Food, Drug, and Cosmetic Act. That inclusion is notable because the statute tightly regulates the pharmaceutical and medical-device industries and is commonly invoked in civil and criminal enforcement actions that concern product safety, labeling, marketing, and related conduct.
The source confirms that the directive’s textual inclusion of this statute is intended to expand or clarify the types of conduct the National Fraud Enforcement Division may pursue, bringing manufacturers and other entities regulated under the statute into clearer view for fraud investigations.
The article describes the DOJ’s historical approach to health fraud enforcement as focusing “centered on providers, clinics, home health agencies, and hospices.” By contrast, the new directive’s explicit statutory citation suggests that the DOJ may now more readily pursue enforcement actions involving companies in the drug and device sectors, rather than principally pursuing cases against care-delivery entities.
The report emphasizes this contrast as a shift in emphasis — which the quoted former official characterized as subtle but meaningful — rather than a wholesale change in criminal enforcement strategy described in operational detail.
Kevin Lowell, who previously spent a decade at the DOJ and served most recently as a deputy chief in the National Fraud Enforcement Division’s health care fraud section, is quoted in the STAT News story calling the change “a subtle but significant expansion” of the division’s jurisdiction. His comment frames the directive as an incremental but important clarification that could broaden the universe of entities subject to fraud scrutiny.
No other named experts or DOJ spokespeople are quoted in the available excerpt.
The STAT News article excerpt available in the source is truncated and indicates the remainder is exclusive to STAT+ subscribers. As reported, the source confirms the directive and the inclusion of the Federal Food, Drug, and Cosmetic Act, but it does not provide several operationally important details. The following were not reported in the accessible text:
Because the full article is behind a STAT+ paywall, readers seeking these specifics must consult the DOJ link cited in the report or access the full subscriber content for a more complete account.
Based on the article’s reporting, the most concrete implication is that drug and device manufacturers should be attentive to increased visibility under DOJ white-collar and health-fraud enforcement if allegations implicate violations of the Federal Food, Drug, and Cosmetic Act. The directive appears to make clear that regulated manufacturers are within the National Fraud Enforcement Division’s scope.
The source does not include prescriptive compliance recommendations, industry reactions, or details about how companies should change internal controls. It also does not report whether the directive will translate immediately into more indictments or civil enforcement actions, or how the division will prioritize cases relative to its existing caseload.
This summary is based solely on the STAT News Pharmalot report and the directive link cited in that article. The STAT News piece is partly behind a STAT+ subscriber paywall; consequently, the source excerpt confirms the directive and expert reaction but does not provide comprehensive text, operational details, or industry responses. For the full directive text and additional reporting, the DOJ link referenced by the STAT article and the full STAT+ article should be consulted.
Source: STAT News Pharmalot report by Ed Silverman (Oct. 7, 2026) and the DOJ directive link cited in that report. The STAT News article notes that additional content is exclusive to STAT+ subscribers and was not reproduced in the available excerpt.